Drug release kinetics and physicochemical characteristics of floating drug delivery systems

Abstract

Developing an efficient floating dosage form is reliant on a better understanding of the relation between formulation variables and performance of the floating systems. Generally, the combination of two buoyancy mechanisms and gas-generating systems with swellable polymers would be beneficial for obtaining an appropriate floating lag time and duration of buoyancy, which in turn guarantees optimum efficiency of the pharmaceutical dosage form.

CuO‐loaded hydrophobically modified chitosan as hybrid carrier for curcumin delivery and anticancer activity

“…The cucumin released in the medium was analyzed at 425 nm by using UV spectrophotometer. The drug release mechanism can be understood by fitting the experimental data with the various drug‐release models such as zero order, first order, Higuchi, Korsmeyer–Peppas and Hixson–Crowell models as represented by Equations 2–6, respectively. where , and are the amounts of drug released at time t and initial and infinite time, respectively.…”

“…The cucumin released in the medium was analyzed at 425 nm by using UV spectrophotometer. The drug release mechanism can be understood by fitting the experimental data with the various drug-release models [26] such as zero order, first order, Higuchi, Korsmeyer-Peppas and Hixson-Crowell models as represented by Equations 2-6, respectively.…”

A Review on Novel Approaches Incorporated in the Formulation of Gastro Retentive Drug Delivery System

“…These formulated dosage forms are known as Gastroretentive drug delivery system which has the capability to couple GRT with drug release for extended time period. [9][10][11][12][13][14][15][16][17] Gastro-retentive drug delivery system (GRDDS) can be defined as a system that retains in the stomach for a sufficient time interval against all the physiological barriers, releasing its active medicament in a controlled manner, and finally metabolized in the body. Along with systemic effect, GRDDS has been used locally to treat gastric and duodenal ulcers, including esophagitis, by eradicating the deeply buried Helicobacter pylori from the sub mucosal tissue of the stomach.…”

Floating capsules containing alginate-based beads of salbutamol sulfate: In vitro–in vivo evaluations

“…have been followed to encourage floatation of the dosage forms in the gastric fluid [14][15][16][17][18][19]. The principal rule is almost constant for all techniques, and that is to provide a density lower than the gastric fluids so that they would be capable of those drugs that act locally in the proximal gastrointestinal tract (GIT), are unstable in the lower part of the gastrointestinal tract, or are poorly absorbed in the intestine [20].…”